Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03161405 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy Participants
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03161405 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 12 participants.
The verdict
NCT03161405, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of the potent cytochrome P-450 (CYP) 3A4 inhibitor (itraconazole) on the single-dose PK of oral TAK-906 maleate.
Interventions
- DRUG Itraconazole
- DRUG TAK-906 Maleate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-06-05 |
| Est. Completion | 2017-07-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03161405
The ClinicalTrials.gov registry entry for NCT03161405 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Itraconazole is the first listed.
NCT03161405 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03161405 about?
NCT03161405 is a clinical study titled "A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy Participants". The purpose of this study is to evaluate the effect of the potent cytochrome P-450 (CYP) 3A4 inhibitor (itraconazole) on the single-dose PK of oral TAK-906 maleate.
What is the current status of trial NCT03161405?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2017-06-05. Estimated completion is 2017-07-10.
What interventions are being tested in trial NCT03161405?
The interventions under investigation include: Itraconazole (DRUG), TAK-906 Maleate (DRUG).
Who is sponsoring clinical trial NCT03161405?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.